Skip to main content

Phase 3 Readout

NVS: Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha

September 10, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
September 10, 2026
Company
Novartis AG (NVS)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha

NVS overview →
Indication
Prostatic Neoplasms

Other upcoming events for NVS

Phase 2 StartPhase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess th
Phase 3 ReadoutPhase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Phase 3 ReadoutPhase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua
Phase 2 StartPhase 2 Start: VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses